This website uses cookies. By continuing to access the site you are agreeing to their use. Learn more about cookies.

Select country
  • language Clinigen France
  • language Clinigen Germany
  • About Clinigen
    • About us
    • History
    • Board of Directors
    • Responsible business
    • Operational excellence
    • Our brands
  • Global offices
    • Australia & New Zealand
    • Mainland Europe
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Careers
    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Investors
    • At a Glance
    • Financial Highlights
    • Investment Case
      • Business Model
      • Our Track Record
      • Market Overview
      • Strategy
      • Our Businesses
    • Share Tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
    • Press Releases
      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
    • Investor Contacts
  • Newsroom
    • Video Library
    • Press Releases
    • Stay In Touch
Clinigen-Logo.png
  • Mission
  • How we can help
    Pharmaceutical & Biotech Companies
    Healthcare Professionals
    Patient Groups
    Patients
  • Medicines & Services
    Commercial Medicines >
    • CARDIOXANE®
    • ETHYOL®
    • FOSCAVIR®
    • GLYCOPYRRONIUM BROMIDE 1MG/5ML ORAL SOLUTION
    • IMUKIN® / IMMUKIN® / IMMUKINE®
    • MELATONIN 1MG/ML ORAL SOLUTION
    • MELATONIN 3MG FILM-COATED TABLETS
    • PROLEUKIN®
    • SAVENE® (Non US)
    • TOTECT® (US only)
    • Partnering with Clinigen
    Unlicensed Medicines >
    • Policy Development
    • Asset Strategy
    • Early Access
    • Real World Evidence
    • Post-Trial Access
    • Phased Launch and Non-Launch Markets
    • Medicine Shortages
    • Market Withdrawal/ Discontinuations
    • Consulting Services
    Clinical Trial Services >
    • Comparator Sourcing and Ancillary Supply
    • Direct-to-site
    • Demand Driven Labelling & Distribution
    • Investigator Initiated Trials
    • Technical Consultancy

    Find a medicine

    Online services for healthcare professionals

    Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Commercial Medicines Special Obtains Aseptics UK
  • Insights
Find a medicine
Hard to find medicines (Clinigen Direct)
Managed Access Programs (Cliniport)
Clinigen Products
  • CARDIOXANE®
  • ETHYOL®
  • FOSCAVIR®
  • GLYCOPYRRONIUM BROMIDE 1MG/5ML ORAL SOLUTION
  • IMUKIN®
  • MELATONIN 1MG/ML ORAL SOLUTION
  • MELATONIN 3MG FILM-COATED TABLETS
  • PROLEUKIN®
  • SAVENE® (Non US)
  • TOTECT® (US only)
  • Partnering with Clinigen
Special Obtains
Aseptics UK
Get in touch
Get in touch
Find a medicine
Hard to find medicines (Clinigen Direct)
Managed Access Programs (Cliniport)
Clinigen Products
  • CARDIOXANE®
  • ETHYOL®
  • FOSCAVIR®
  • GLYCOPYRRONIUM BROMIDE 1MG/5ML ORAL SOLUTION
  • IMUKIN®
  • MELATONIN 1MG/ML ORAL SOLUTION
  • MELATONIN 3MG FILM-COATED TABLETS
  • PROLEUKIN®
  • SAVENE® (Non US)
  • TOTECT® (US only)
  • Partnering with Clinigen
Special Obtains
Aseptics UK
  • Mission
  • How we can help
    How we can help
    • Pharmaceutical & Biotech Companies
    • Healthcare Professionals
    • Patient Groups
    • Patients
  • Medicines & Services
    Medicines & Services
    • Commercial Medicines >
      Commercial Medicines >

      Commercial Medicines >

      • CARDIOXANE®
      • ETHYOL®
      • FOSCAVIR®
      • GLYCOPYRRONIUM BROMIDE 1MG/5ML ORAL SOLUTION
      • IMUKIN® / IMMUKIN® / IMMUKINE®
      • MELATONIN 1MG/ML ORAL SOLUTION
      • MELATONIN 3MG FILM-COATED TABLETS
      • PROLEUKIN®
      • SAVENE® (Non US)
      • TOTECT® (US only)
      • Partnering with Clinigen
    • Unlicensed Medicines >
      Unlicensed Medicines >

      Unlicensed Medicines >

      • Policy Development
      • Asset Strategy
      • Early Access
      • Real World Evidence
      • Post-Trial Access
      • Phased Launch and Non-Launch Markets
      • Medicine Shortages
      • Market Withdrawal/ Discontinuations
      • Consulting Services
    • Clinical Trial Services >
      Clinical Trial Services >

      Clinical Trial Services >

      • Comparator Sourcing and Ancillary Supply
      • Direct-to-site
      • Demand Driven Labelling & Distribution
      • Investigator Initiated Trials
      • Technical Consultancy

    Find a medicine

    Online services for healthcare professionals

    Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Commercial Medicines Special Obtains Aseptics UK
  • Insights
  • About Clinigen
    About Clinigen

    About Clinigen

    • About us
    • History
    • Board of Directors
    • Responsible business
    • Operational excellence
    • Our brands
  • Global offices
    Global offices

    Global offices

    • Australia & New Zealand
    • Mainland Europe
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Careers
    Careers

    Careers

    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Investors
    Investors

    Investors

    • At a Glance
    • Financial Highlights
    • Investment Case
      Investment Case

      Investment Case

      • Business Model
      • Our Track Record
      • Market Overview
      • Strategy
      • Our Businesses
    • Share Tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
    • Press Releases
      Press Releases

      Press Releases

      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      Shareholder Services

      Shareholder Services

      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      Corporate Governance

      Corporate Governance

      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
    • Investor Contacts
  • Newsroom
    Newsroom

    Newsroom

    • Video Library
    • Press Releases
    • Stay In Touch

Press Releases

  • At a Glance
  • Financial Highlights
  • Investment Case
    • Business Model
    • Our Track Record
    • Market Overview
    • Strategy
    • Our Businesses
  • Share Tools
  • Results, Reports and Presentations
  • Quantum Archive
  • Financial Calendar
  • Press Releases
    • Press Releases
    • Regulatory News
    • Email Alerts
  • Shareholder Services
    • AGM
    • Registrar Services
    • Major Shareholders
    • Advisor Contacts
    • Analyst Coverage
  • AIM Rule 26
  • Corporate Governance
    • Corporate Governance Statement
    • Board of Directors
    • Tax Strategy
  • Investor Contacts
  • 2019
  • 2018
  • 2017
  • Archive
More
Filter by
  • 19 Sep 2019

    Full Year Results for the 12 Months Ended 30 June 2019
    Related materials
    PDF (664.17KB) Presentation Webcast
  • 02 Sep 2019

    Clinigen signs exclusive distribution agreement with CHEPLAPHARM to distribute Etopophos® and Vepesid® in Australia and New Zealand
    Related materials
    PDF (177.17KB)
  • 05 Aug 2019

    Notification of Full Year Results Date
    Related materials
    PDF (140.26KB)
  • 16 Jul 2019

    Year end trading update

    Related materials
    PDF (419.88KB)
  • 26 Jun 2019

    MHRA licenses two Melatonin products indicated for short-term jet-lag treatment in adults
    Related materials
    PDF (176.52KB)
  • 24 Jun 2019

    Clinigen broadens partnership with Accord Healthcare to supply and distribute Cardioxane® and Savene® in Poland
    Related materials
    PDF (180.01KB)
  • 15 May 2019

    Clinigen to assume control of US commercial rights of Ethyol® and Totect® by Q4 2019
    Related materials
    PDF (289.08KB)
  • 01 May 2019

    Clinigen appoints James Meyer as General Manager of Commercial Medicines in the US
    Related materials
    PDF (518.62KB)
  • 11 Apr 2019

    Clinigen and GC Pharma sign exclusive licensing agreement for Hunterase (Idursulfase-beta) ICV in Japan
    Related materials
    PDF (328.94KB)
  • 02 Apr 2019

    Clinigen completes acquisition of US rights to Proleukin

    Related materials
    PDF (547.74KB)
Our global offices
  • Australia & New Zealand
  • Mainland Europe
  • Japan
  • Singapore
  • South Africa
  • United Kingdom
  • United States
Site
tools
  • Stay In Touch
  • AE Reporting
  • Medical enquiries
  • Terms of use
  • Cookies
  • Privacy policy
  • UK Gender Pay Gap Report
  • Modern Slavery Statement
  • Access Online
  • Sitemap
  • Consumer Information Obligations
Find a medicine

Online services for healthcare professionals

Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Clinigen Products Special Obtains Aseptics UK
  • Twitter
  • Vimeo
  • Linkedin
© Copyright 2019 Clinigen Group plc. By Emperor